Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients

Clinical Rheumatology

Volumn 34, Issue 3, 2015, Pages 585-589

  Rebman, Alison W ^a   Crowder, Lauren A ^a   Kirkpatrick, Allison ^a   Aucott, John N ^b  

^a Lyme Disease Research Foundation   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Borrelia burgdorferi; Lyme disease; Seroconversion

Indexed keywords

ANTIINFECTIVE AGENT; DOXYCYCLINE;

ADULT; AGED; BORRELIA BURGDORFERI; FEMALE; HUMAN; IMMUNOLOGY; LYME DISEASE; MALE; MIDDLE AGED; PROSPECTIVE STUDY; SEROCONVERSION; SYNDROME; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; DOXYCYCLINE; FEMALE; HUMANS; LYME DISEASE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEROCONVERSION; SYNDROME; YOUNG ADULT;

EID: 84939876052     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2706-z     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention (2013) Notice to readers: final 2012 reports of nationally notifiable infectious diseases. Morb Mortal Wkly Rep 62:669–682
2. Bacon R, Kugeler K, Mead P (2008) Surveillance for lyme disease—United States, 1992–2006. Morb Mortal Wkly Rep 57:1–9
3. Steere AC (2001) Lyme disease. N Engl J Med 345:115–125. doi:10.1056/NEJM200107123450207
4. Wormser GP, Nowakowski J, Nadelman RB et al (2008) Impact of clinical variables on Borrelia burgdorferi-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease. Clin Vaccine Immunol 15:1519–1522. doi:10.1128/CVI.00109-08
5. Dinerman H, Steere AC (1992) Lyme disease associated with fibromyalgia. Ann Intern Med 117:281–285
6. Centers for Disease Control and Prevention (1995) Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. Morb Mortal Wkly Rep 44:590–591
7. Aguero-Rosenfeld ME, Nowakowski J, Bittker S et al (1996) Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 34:1–9
8. Kalish RA, McHugh G, Granquist J et al (2001) Persistence of immunoglobulin M or Immunoglobulin G Antibody responses to Borrelia Burgdorferi 10–20 years after active Lyme disease. Clin Infect Dis 33:780–785. doi:10.1086/322669
9. Aberer E, Schwantzer G (2012) Course of antibody response in Lyme Borreliosis patients before and after therapy. ISRN Immunol 2012:1–4. doi:10.5402/2012/719821
10. Schwarzwalder A, Schneider M (2010) Sex differences in the clinical and serologic presentation of early lyme disease: results from a retrospective review. Gend Med 7:320–329. doi:10.1016/j.genm.2010.08.002
11. Jarefors S, Bennet L, You E et al (2006) Lyme borreliosis reinfection: might it be explained by a gender difference in immune response? Immunology 118:224–232. doi:10.1111/j.1365-2567.2006.02360.x
12. Aucott J, Seifter A, Rebman A (2012) Probable late lyme disease: a variant manifestation of untreated Borrelia burgdorferi infection. BMC Infect Dis 12:173. doi:10.1186/1471-2334-12-173
13. Strle F, Wormser GP, Mead P, Dhaduvai K (2013) Gender disparity between cutaneous and non-cutaneous manifestations of Lyme Borreliosis. PLoS One 8:e64110. doi:10.1371/journal.pone.0064110
14. Bennet L, Stjernberg L, Berglund J (2007) Effect of gender on clinical and epidemiologic features of Lyme borreliosis. Vector Borne Zoonotic Dis 7:34–41
15. Kuehn BM (2013) CDC estimates 300,000 US cases of Lyme disease annually. J Am Med Assoc 310:1110. doi:10.1001/jama.2013.278331